Do Beta Blockers Raise Blood Sugar?

Beta blockers, as a class, tend to push blood sugar upward and worsen the body’s response to insulin. A large meta-analysis of nearly 95,000 patients with high blood pressure found that beta-blocker therapy raised the risk of developing new-onset diabetes by about 22% compared with other non-diuretic blood pressure drugs.¹ The effect is real, but the picture is more complicated than a blanket warning. Which beta blocker you take, what other medications you’re on, and your individual metabolic profile all shape how much your blood sugar is affected.

How Beta Blockers Interfere With Blood Sugar

The metabolic trouble with beta blockers comes from several overlapping mechanisms, not one single switch. The most direct involves insulin release itself. Pancreatic beta cells rely on a signaling pathway that involves beta-2 receptors. When a beta blocker, especially a non-selective one, blocks those receptors, it blunts the first burst of insulin your pancreas normally puts out in response to rising blood sugar.² Less insulin at the right moment means glucose lingers in the bloodstream longer than it should.

Beyond insulin release, beta blockers can also make your tissues less responsive to the insulin that is circulating. In a controlled trial of obese people with high blood pressure, atenolol significantly worsened fasting glucose and fasting insulin levels over the treatment period, while perindopril (an ACE inhibitor) did not.³ This pattern of higher glucose and higher insulin at the same time is a hallmark of worsening insulin resistance: the body is pumping out more insulin but getting less effect from it.

There’s also a slower, indirect route. Beta blockers can reduce your resting metabolic rate by roughly 10%, and across trials that tracked weight, they’re associated with an average gain of about 1.2 kilograms.⁴ Extra weight, particularly around the abdomen, compounds insulin resistance. So even if the direct metabolic hit were small, the weight creep can amplify the problem over months and years. These effects also tend to be dose-dependent: higher doses generally mean more metabolic disruption.⁵

Not All Beta Blockers Are the Same

One of the most important things to understand is that “beta blocker” covers a wide range of drugs that vary dramatically in how they affect your metabolism. The distinction that matters most is selectivity: which types of beta receptors a drug blocks.

Older, non-selective beta blockers like propranolol block both beta-1 receptors (mostly in the heart) and beta-2 receptors (found in the lungs, blood vessels, liver, and pancreas). Blocking beta-2 receptors is where most of the glucose trouble comes from. In a classic comparison, propranolol significantly delayed blood sugar recovery after insulin-induced hypoglycemia, while metoprolol, a beta-1 selective drug, did not cause a significant delay.⁶ The researchers concluded bluntly that propranolol “is hazardous in subjects prone to hypoglycaemia” and that anyone with diabetes who needs a beta blocker should get a beta-1 selective one.

Separate work in healthy volunteers confirmed the pattern: propranolol prolonged the hypoglycemic response to insulin more than atenolol did, and propranolol delayed the recovery of free fatty acids (an alternative fuel source for the body during low blood sugar) while atenolol had no significant effect on them.⁷ So even among older beta blockers, the selective ones cause noticeably less metabolic harm.

Third-Generation Beta Blockers

The picture improves further with newer, so-called third-generation beta blockers. Nebivolol and carvedilol both have properties beyond simple beta-blockade: nebivolol promotes nitric oxide release in blood vessels, and carvedilol blocks alpha receptors as well, which helps keep blood vessels relaxed. These extra mechanisms appear to offset much of the insulin resistance seen with traditional beta blockers.

In a head-to-head comparison, metoprolol significantly worsened insulin sensitivity over 12 weeks, while nebivolol did not change it at all.⁸ In heart failure patients without diabetes, nebivolol actually improved insulin resistance markers, with the insulin resistance index (HOMA-IR) dropping by nearly 12% over three months, while carvedilol nudged it slightly in the wrong direction.⁹ Another trial in patients with essential hypertension found that both carvedilol and nebivolol improved glucose, insulin, and lipid measures similarly after treatment.¹⁰

A retrospective study of people with type 2 diabetes found that bisoprolol (a highly beta-1 selective blocker) was associated with greater reductions in HbA1c and fasting glucose compared to no treatment, and that carvedilol users showed an even larger HbA1c reduction than bisoprolol users.¹¹ So the choice of specific beta blocker can mean the difference between blood sugar getting worse, staying flat, or even improving modestly.

What This Means If You Already Have Diabetes

People who already have diabetes face a double concern: beta blockers can worsen their glucose control, and they can also interfere with the body’s recovery from low blood sugar episodes. A systematic review and meta-analysis found that beta blockers increased HbA1c by an average of 0.75 percentage points compared with placebo.¹² For context, a 0.75% jump in HbA1c is a clinically meaningful worsening of control, roughly the difference between “well-managed” and “needs medication adjustment” for many patients.

That said, this is an average across different beta blockers, and as discussed above, newer agents like nebivolol and carvedilol perform considerably better. The practical takeaway for someone with diabetes: if your doctor prescribes a beta blocker for heart failure, post-heart-attack protection, or rate control, the benefit often outweighs the metabolic cost, but the specific drug chosen should account for your glucose situation.

The Hypoglycemia Problem

If you take insulin or sulfonylurea drugs that can cause low blood sugar, beta blockers introduce a specific hazard that goes beyond simply raising average glucose. When blood sugar drops, your body normally mounts a counter-regulatory response. Adrenaline surges, the liver releases stored glucose, and you feel telltale warning signs: a racing heart, trembling hands, sweating. Beta blockers can mask several of those symptoms by blocking the adrenergic signals that produce them. The fast heartbeat, in particular, is often blunted.

More than masking symptoms, non-selective beta blockers actively slow the recovery from hypoglycemia. Propranolol was shown to reduce the liver’s rebound glucose output by about 70% during recovery from insulin-induced low blood sugar in diabetic subjects, essentially keeping blood sugar dangerously low for longer than it would otherwise remain.¹³ The mechanism in healthy people is somewhat different, working more through increased tissue glucose uptake, but the end result is the same: slower recovery.¹⁴

This is why non-selective beta blockers are generally avoided in people with insulin-treated diabetes whenever possible. If a beta blocker is medically necessary, a beta-1 selective agent like metoprolol or bisoprolol is strongly preferred, since the interference with hypoglycemia recovery is much less pronounced with those drugs.

When Beta Blockers Are Combined With Diuretics

The metabolic hit from beta blockers gets worse when they’re paired with thiazide diuretics, a combination that was once among the most popular first-line treatments for high blood pressure. Thiazides can independently raise blood sugar and worsen potassium levels, and combining them with a beta blocker compounds both problems. A meta-analysis found that treatment regimens combining thiazides and beta blockers carry a significantly greater risk of new-onset diabetes than regimens that avoid this pairing.¹⁵ Research in hypertensive patients with abdominal obesity specifically confirmed that thiazides alone or with beta blockers impaired glucose metabolism.¹⁶

This evidence has shifted prescribing habits. Current guidelines generally discourage the beta-blocker-plus-thiazide combination as initial therapy for high blood pressure, particularly in people who are overweight or have prediabetes, precisely because the metabolic risks stack up. If you’re on both and your blood sugar has been creeping upward, it’s a conversation worth having with your doctor.

Can Other Medications Offset the Glucose Effect?

There’s an interesting counterpoint involving ACE inhibitors, a different class of blood pressure drug. In a large study of patients with stable coronary artery disease, those taking beta blockers who were also assigned to the ACE inhibitor trandolapril had a much lower risk of developing new-onset diabetes than beta-blocker users on placebo. Among beta-blocker users without ACE inhibitor protection, the hazard ratio for new diabetes was 1.63, meaning a 63% higher risk. Adding the ACE inhibitor brought that down to a statistically non-significant 1.11.¹⁷ The mechanism appears to involve the renin-angiotensin system’s own effects on insulin signaling, essentially pulling in a metabolically favorable direction to counterbalance the beta blocker’s unfavorable one.

This doesn’t mean ACE inhibitors are prescribed just to fix a beta blocker’s glucose problem, but many patients with heart disease or high blood pressure already have reasons to take both. When they do, the ACE inhibitor may be providing a protective metabolic side benefit.

A Nuance Worth Knowing About the Diabetes Risk Data

It’s worth flagging that the story around beta blockers and new-onset diabetes isn’t perfectly clean. The headline figure, that roughly 22% increased risk from the large meta-analysis, comes from comparisons with other antihypertensive drugs.¹ But a reanalysis of data from the NAVIGATOR trial, which specifically followed patients with impaired glucose tolerance (people already on the path toward diabetes), found that after adjusting for multiple factors, beta blockers were not independently associated with new-onset diabetes in that population, while diuretics and statins were.¹⁸

How do you reconcile those findings? Partly it’s about population: the NAVIGATOR subjects were already metabolically compromised, so the incremental push from beta blockers may have been drowned out by the much larger metabolic forces already at play. Partly it’s about which beta blockers were used and at what doses. And partly it’s about what you compare against. When beta blockers are measured against ACE inhibitors or calcium channel blockers, which may themselves improve or at least not worsen glucose metabolism, the beta blocker looks worse by contrast. When measured against placebo in people who are already prediabetic, the signal gets weaker. The honest read is that beta blockers create a real but modest metabolic headwind, and whether that headwind matters clinically depends heavily on the individual patient.

Exercise and Blood Sugar on Beta Blockers

If you exercise regularly and take a beta blocker, the glucose effects extend into your workouts. Beta blockers, especially non-selective ones, can increase glucose uptake by exercising muscle. In people with type 1 diabetes, the greater fall in blood sugar during exercise after beta-blocking drugs was attributed largely to a direct effect of beta-2 blockade on muscle, increasing the exercise-induced rise in glucose disposal.¹⁹ This means that if you’re on a non-selective beta blocker and you exercise vigorously, your blood sugar may drop more sharply than you’d expect, and the usual warning signs of a low may be dampened.

For people without diabetes, this effect is rarely dangerous. You might feel more fatigued during exercise (partly because your heart rate can’t climb as high), but blood sugar typically stays in a safe range. For anyone on insulin or insulin-stimulating medications, though, it’s worth monitoring glucose around workouts more closely when starting a beta blocker, and discussing carbohydrate strategies with your care team.

Genetics and Individual Susceptibility

Not everyone who takes a beta blocker gets the same metabolic hit, and researchers have started looking at why. A study combining metabolic and genetic data identified a specific genetic variant (in a gene called DPYS) that was associated with significantly higher glucose levels after treatment with atenolol. Carriers of a particular version of this gene saw meaningfully greater blood sugar increases compared to non-carriers.²⁰ This kind of pharmacogenomic work is still in early stages, but it points toward a future where a genetic test might help predict who is most vulnerable to beta-blocker-induced glucose problems, allowing more tailored prescribing.

For now, clinical practice relies on cruder signals: your weight, your family history of diabetes, your fasting glucose and HbA1c before starting the drug, and regular monitoring after. If you’re already borderline, your doctor should be checking metabolic markers more frequently once a beta blocker is started.

Beta Blockers in Pregnancy and Neonatal Blood Sugar

Beta blockers are sometimes used during pregnancy for conditions like high blood pressure or certain heart rhythm problems. The glucose question arises in a different form here: not for the mother, but for the newborn. A study of over 2,200 beta-blocker-exposed pregnancies found that the risk of neonatal hypoglycemia was about 4.3% in exposed newborns versus 1.2% in unexposed ones. Even after adjusting for confounding factors, the risk of neonatal hypoglycemia remained nearly 70% higher in the exposed group.²¹ This means newborns of mothers who take beta blockers in late pregnancy generally need blood sugar monitoring after delivery. The hypoglycemia is usually brief and treatable, but it reinforces that these drugs’ metabolic effects extend beyond the person swallowing the pill.

The risk of neonatal bradycardia (slow heart rate) was also elevated in the same study, consistent with the beta-blocking effect crossing the placenta. Obstetricians factor these risks into the decision, but for conditions where the benefit to the mother is clear, the neonatal risks are considered manageable with appropriate monitoring.